accountProactive Investors USA & Canada Acadia Reports Positive Results for Antipsychotic Drug Wall Street Journal Acadia Pharmaceuticals Inc. said its experimental antipsychotic drug showed significant improvement in patients with Parkinson's disease psychosis in a late-stage trial. Shares of Acadia surged to $5.62 in midday trading Tuesday, up from Monday's close ... Acadia surges on Parkinson's...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Acadia Reports Positive Results for Antipsychotic Drug - Wall Street Journal
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account